2 Healthcare Stocks Poised for a Comeback in 2026
2026-01-22 13:25:00 ET
Zoetis (NYSE: ZTS) and Regeneron Pharmaceuticals (NASDAQ: REGN) are two healthcare leaders that have lagged broader equities over the past 12 months, as both encountered headwinds that led to worse-than-expected financial results. However, following recent developments, Zoetis and Regeneron look much better than they did six months ago, and both could bounce back this year. Let's find out why.
Image source: Getty Images.
Zoetis is a leading animal health company with a vast portfolio of products across several categories, including fish, poultry, and livestock. Still, everyone knows that the company's most important business segment is companion animals. Last year, two of Zoetis' key growth drivers, Librela and Solensia, encountered challenges. Librela treats osteoarthritis (OA) pain in dogs, and Solensia targets OA pain in cats.
NASDAQ: ZTS
ZTS Trading
1.62% G/L:
$116.965 Last:
810,167 Volume:
$115.61 Open:
